45 CFR § 180 compliance
F · 55
This hospital published little of what § 180 requires.
●Machine-readable file published
○Gross / standard charges
○Discounted cash price
●Payer-specific negotiated rates
○Min / max negotiated charges
●Free, public, no login required
Procedures listed
15,074
Insurances with rates
4
CPT / HCPCS codes
13,465
Source MRF
Most expensive procedures (gross)
| Code | Description | Gross | Cash | Min payer | Max payer | # insurers |
|---|---|---|---|---|---|---|
| J2326 | NUSINERSEN (PF) 12 MG/5 ML INTRATHECAL SOLUTION | $852,442 | $681,954 | — | — | 2 |
| J9226 | HISTRELIN 50 MG (65 MCG/DAY) IMPLANT KIT | $342,482 | $273,985 | — | — | 3 |
| C9293 | GLUCARPIDASE 1,000 UNIT INTRAVENOUS SOLUTION | $247,259 | $197,807 | — | — | 0 |
| J9043 | CABAZITAXEL 10 MG/ML (FIRST DILUTION) INTRAVENOUS SOLUTION | $199,106 | $159,285 | — | — | 3 |
| J3357 | USTEKINUMAB 90 MG/ML SUBCUTANEOUS SYRINGE | $167,272 | $133,818 | — | — | 2 |
| J9347 | TREMELIMUMAB-ACTL 20 MG/ML INTRAVENOUS SOLUTION | $140,285 | $112,228 | — | — | 3 |
| J9228 | IPILIMUMAB 200 MG/40 ML (5 MG/ML) INTRAVENOUS SOLUTION | $122,899 | $98,319 | — | — | 3 |
| J2350 | OCRELIZUMAB 30 MG/ML INTRAVENOUS SOLUTION | $118,501 | $94,801 | — | — | 2 |
| C1825 | SYS BAROSTIM NEO | $108,025 | $86,420 | — | — | 0 |
| J3245 | TILDRAKIZUMAB-ASMN 100 MG/ML SUBCUTANEOUS SYRINGE | $103,640 | $82,912 | — | — | 2 |
| J9118 | CALASPARGASE PEGOL-MKNL 750 UNIT/ML INTRAVENOUS SOLUTION | $102,681 | $82,145 | — | — | 0 |
| J9359 | LONCASTUXIMAB TESIRINE-LPYL 10 MG INTRAVENOUS SOLUTION | $98,237 | $78,590 | — | — | 3 |
| 33289 | TCAT IMPL WRLS P-ART PRS SNR | $98,160 | $78,528 | — | — | 4 |
| J9334 | EFGARTIGIMOD ALFA 1008 MG-HYALURON-QVFC 11,200 UNIT/5.6 ML SUBCUT SOLN | $96,746 | $77,397 | — | — | 3 |
| J9266 | PEGASPARGASE 750 UNIT/ML INJECTION SOLUTION | $94,908 | $75,926 | — | — | 2 |
| C1767 | DEMIPULSE W/PT KIT | $83,863 | $67,090 | — | — | 0 |
| 33231 | INSRT PULSE GEN W/MULTI LEADS | $80,895 | $64,716 | — | — | 5 |
| 33270 | SUBQ ICD INSERT W/SUB ELECTRODE | $80,895 | $64,716 | — | — | 5 |
| 33249 | IMPLT DFIB SYS IMPL DUAL GEN+LEA | $80,895 | $64,716 | — | — | 8 |
| 33264 | RMV&RPL IMPLT DFIB GEN MULT LEAD | $80,895 | $64,716 | — | — | 6 |
| 93654 | COMPRE EP EVAL TX VT | $80,340 | $64,272 | — | — | 4 |
| 93653 | COMPRE EP EVAL TX SVT | $80,340 | $64,272 | — | — | 4 |
| 93656 | COMPRE EP EVAL ABLTJ ATR FIB | $80,340 | $64,272 | — | — | 4 |
| J9229 | INOTUZUMAB OZOGAMICIN 0.9 MG(0.25 MG/ML INITIAL CONCENTRATION) IV SOLN | $80,047 | $64,037 | — | — | 2 |
| 0823T | TCAT INS 1CHMBR LDLS PM RA | $73,037 | $58,429 | — | — | 2 |
| 0825T | TCAT RMVL&RPL 1CHMB LDLS PM RA | $73,037 | $58,429 | — | — | 2 |
| C1769 | GRAFT AORTOILIAC | $70,185 | $56,148 | — | — | 0 |
| 33362 | TAVR OPEN FEMERAL APP | $67,373 | $53,899 | — | — | 0 |
| 33363 | TAVR PERCUTANEOUS AXILLARY APP | $67,373 | $53,899 | — | — | 0 |
| 33364 | TAVR PERCUTANEOUS ILIAC APP | $67,373 | $53,899 | — | — | 0 |
| J9350 | MOSUNETUZUMAB-AXGB 1 MG/ML INTRAVENOUS SOLUTION | $65,317 | $52,253 | — | — | 5 |
| J9309 | POLATUZUMAB VEDOTIN-PIIQ 140 MG INTRAVENOUS SOLUTION | $64,298 | $51,438 | — | — | 3 |
| J2329 | UBLITUXIMAB-XIIY 25 MG/ML INTRAVENOUS SOLUTION | $63,050 | $50,440 | — | — | 2 |
| J2327 | RISANKIZUMAB-RZAA 60 MG/ML INTRAVENOUS SOLUTION | $60,933 | $48,747 | — | — | 3 |
| C2624 | SYS CARDIAC PULMONARY ARTERY SENSOR DELIVERY | $59,250 | $47,400 | — | — | 0 |
| C1882 | DEFIB CLARIA MRI CRT ALA CARTE | $59,073 | $47,258 | — | — | 0 |
| J0222 | PATISIRAN (LIPID COMPLEX) 2 MG/ML INTRAVENOUS SOLUTION | $58,925 | $47,140 | — | — | 2 |
| 33263 | RMV&RPL IMPLT DFIB GEN DUAL LEAD | $57,959 | $46,367 | — | — | 6 |
| 33262 | RMV&RPL IMPLT DFIB GEN SING LEAD | $57,959 | $46,367 | — | — | 5 |
| 33240 | DEFIB IMPLANT SNGL GEN ONLY | $57,959 | $46,367 | — | — | 5 |
| 33230 | INSRT PULSE GEN W/DUAL LEADS | $57,959 | $46,367 | — | — | 6 |
| J9321 | EPCORITAMAB-BYSP 48 MG/0.8 ML SUBCUTANEOUS SOLUTION | $57,605 | $46,084 | — | — | 3 |
| J1930 | LANREOTIDE 120 MG/0.5 ML SUBCUTANEOUS SYRINGE | $57,587 | $46,070 | — | — | 2 |
| C9765 | REVASC INTRA LITHOTRIP-STENT | $55,344 | $44,275 | — | — | 2 |
| C9766 | REVASC INTRA LITHOTRIP-ATHER | $55,344 | $44,275 | — | — | 3 |
| C9767 | REVASC LITHOTRIP-STENT-ATHER | $55,344 | $44,275 | — | — | 2 |
| C9774 | REVASC LITHOTR-ATHER TIB/PER | $54,433 | $43,546 | — | — | 3 |
| C9775 | REVASC LITH-STENT-ATH TIB/PER | $54,433 | $43,546 | — | — | 2 |
| C9773 | REVASC LITHOTR-STENT TIB/PER | $54,433 | $43,546 | — | — | 3 |
| C2616 | SIR SPHERES MICROSPHERES | $53,985 | $43,188 | — | — | 2 |
Showing top 50 of 15,074 priced procedures, sorted by gross charge.
Data straight from this hospital's federally-mandated machine-readable file (45 CFR § 180). The compliance grade reflects how completely the hospital published the six required data elements, not the quality of care.